

31st ANNUAL MEETING - AAS
of the
Austrian Atherosclerosis Society



May 2 – 4, 2024
St. Gilgen / Wolfgangsee

www.aas.at

Organisationskomitee:

Dagmar Kratky
Renate Schreiber

Programmkomitee:

Marion Mußbacher
Johanna Schachtl-Riess
Dimitris Tsiantoulas

Tagungsort:

Seehotel Billroth (Untergeschoss)
Billrothstraße 2, 5340 St. Gilgen

Tagungsbüro, Anmeldung & Sponsoring:

Medizinische Ausstellungs- und Werbegesellschaft

Freyung 6, 1010 Wien

Tel.: +43-1-536 63-37

E-Mail: maw@media.co.at

Web: www.maw.co.at

AAS – Gesellschaftssekretariat:

AAS – Austrian Atherosclerosis Society
c/o MAW

ZVR-Zahl: 179890279

Kontakt: Frau Katrin Doppler

Freyung 6, 1010 Wien

Tel.: +43-1-536 63-37

E-Mail: aas@media.co.at

Web: www.aas.at

Online-Anmeldung: <https://registration.maw.co.at/athero24>

Liebe Kolleginnen und Kollegen,

Im Namen des Organisations- und Programmkomitees dürfen wir Sie herzlich zur 31. Jahrestagung der Österreichischen Atherosklerose Gesellschaft (AAS) vom 2. – 4. Mai 2024 einladen. Durch die Ausweitung der Tagung haben wir heuer etwas mehr Zeit für Networking und Projektbesprechungen und hoffen, dass diese Möglichkeiten von allen Teilnehmenden genutzt werden. Leider wird unsere Jahrestagung zum letzten Mal an unserem traditionellen Tagungsort im schönen St. Gilgen stattfinden.

Die Themen der eingeladenen Sprecher:innen umfassen aktuelle Erkenntnisse über braunes Fettgewebe als Ziel bei kardiometabolischen Erkrankungen (Patrick Rensen, Leiden, Niederlande), die physiologische und pathophysiologische Rolle von nicht-kodierenden RNAs im kardiovaskulären System (Stephanie Dimmeler, Frankfurt, Deutschland) und die Möglichkeiten von Biomarkern zur Bestimmung des Restrisikos (Wolfgang König, München, Deutschland). Ein weiteres Highlight wird der Vortrag von Gerd Utermann (Innsbruck, Österreich) über die Geschichte der Entdeckung und Charakterisierung der ApoE und Apo(a)/Lp(a) Polymorphismen. Wie auch in den vergangenen Jahren werden die Präsentationen aktueller Forschungsergebnisse von Kongressteilnehmer:innen den wesentlichen Bestandteil des Programms bilden. Unser Treffen bietet allen Teilnehmer:innen die Möglichkeit in einem schönen und entspannten Rahmen zu präsentieren, neue Forschungsergebnisse zu hören, von anderen zu lernen, Kontakte zu knüpfen und Spaß zu haben.

Für die Veranstaltung wurden 12 DFP-Punkte registriert.

Wir möchten uns besonders bei unseren Sponsoren bedanken, ohne die es nicht möglich wäre, unsere Jahrestagung abzuhalten. Wir freuen uns auf eine interessante Tagung und sehen uns bald in St. Gilgen.


Dear colleagues and friends,

On behalf of the organizing and program committee, we would like to cordially invite you to the 31st Annual Meeting of the Austrian Atherosclerosis Society (AAS) on May 2-4, 2024. By extending the conference this year, we have a little more time for networking and project discussions and hope that all participants will take advantage of these opportunities. Unfortunately, our annual conference will take place for the last time at our traditional venue in beautiful St. Gilgen.

The topics presented by our invited speakers include recent findings on brown adipose tissue as a target in cardiometabolic diseases (Patrick Rensen, Leiden, The Netherlands), the physiological and pathophysiological role of non-coding RNAs in the cardiovascular system (Stephanie Dimmeler, Frankfurt, Germany) and the possibilities of biomarkers to determine residual risk (Wolfgang König, Munich, Germany). Another highlight will be the lecture by Gerd Utermann (Innsbruck, Austria) on the history of the discovery and characterization of ApoE and Apo(a)/Lp(a) polymorphisms. As in previous years, the presentations of recent research results by congress participants will form an essential part of the program. Our meeting offers all participants the opportunity to present, hear new research results, learn from others, socialize and have fun in a nice and relaxed setting.

12 DFP points have been registered for this event.

We would especially like to thank our sponsors, without whom it would not be possible to hold our annual meeting. We are looking forward to an interesting conference and see you soon in St. Gilgen.



Univ.-Prof. Dr. Dagmar Kratky
President AAS



Dr. Renate Schreiber
Secretary AAS

Für Kongressorganisation und Betreuung vor Ort ist wie in den vergangenen Jahren die Firma MAW verantwortlich.

Die Jahrestagung findet wieder im Raum Wolfgangsee statt. Der Zugang zu den Seminarräumlichkeiten im Untergeschoss erfolgt über das Stiegenhaus gegenüber der Rezeption.

Für Mitglieder der AAS wird ein Unkostenbeitrag von 80 € eingehoben; die Tagungsgebühr für Nichtmitglieder beträgt 160 €. Die jährliche AAS Mitgliedsgebühr beträgt 40 € (ordentliches Mitglied) bzw. 20 € (studentisches Mitglied).

Wir bitten Sie, den Unkostenbeitrag & Ihre Mitgliedsgebühr vor Ort an der Registratur zu begleichen. Bitte um Beachtung, dass die Bezahlung nur in bar möglich ist.

Die Kosten für die Nächtigung von 2. – 4. Mai werden für Abstract-Präsentatoren und AAS Mitglieder von der AAS getragen; Telefon, Minibar und weitere Konsumationen werden individuell verrechnet.

Poster: bitte um Demontage Ihres Posters bis 12 Uhr am Samstag, den 4. Mai 2024. Andernfalls wird Ihr Poster entsorgt.

Our partner MAW is again in charge for the congress organisation and on-site support.

Our congress will be held in the room “Wolfgangsee” (lower level), which can be accessed via the staircase opposite the reception desk.

We kindly ask you to pay your contribution towards expenses in cash on site. (AAS members € 80.–, non-members € 160.–). The annual AAS membership is also to be paid in cash on site at the registration desk (regular member € 40.–, students € 20.–).

For all AAS members and abstract presenters, the AAS will cover the costs of accommodation from May 2–4, 2024 and the society evening on Friday (further costs like phone, mini-bar or other consumptions have to be paid individually).

Posters: please remove your poster until midday on Saturday, May 4, 2024. Otherwise your poster will be disposed of.

15:00 - 15:05	Welcome address by the AAS president Dagmar Kratky
15:05 - 18:20	Session 1: Lipoprotein metabolism Chairs: Dagmar Kratky and Florian Kronenberg
15:05 - 15:50	Historical lecture Gerd Utermann Medical University of Innsbruck, Austria <i>A short history of the apoE and apo(a)/Lp(a) polymorphisms</i>
15:50 - 16:50	Short talks 1-4 (10 min. talk + 5 min. discussion) Adriana Koller Medical University of Innsbruck, Austria <i>Exploring the role of Apolipoprotein A-IV in cardiovascular disease: Insights from a population-based meta-analysis</i> Lukas Schmidt Medical University of Vienna, Austria <i>Beyond LDL-cholesterol: effects of alirocumab on the human apolipoproteome</i> Azin Kheirkhah Medical University of Innsbruck, Austria <i>Meta-GWAS on PCSK9 concentrations reveals associations of novel loci outside the PCSK9 locus in white populations</i> Thomas Plattner VIVIT Feldkirch, Austria <i>The ApoB/LDL-C ratio predicts cardiovascular events in coronary artery disease patients independent of type 2 diabetes status</i>
16:50 - 17:20	Coffee break & Exhibition

17:20 - 18:20 **Short talks 5-8** **(10 min. talk + 5 min. discussion)**

Franz Radner

University of Graz, Austria

The defective targeting of PNPLA1 transacylase by ABHD5 to lipid droplets drives ichthyosis in Chanarin-Dorman syndrome

Julia Stadler

Medical University of Graz, Austria

Low apolipoprotein M is associated with incident cardiovascular events in patients with chronic kidney disease

Katharina B. Kuentzel

University of Copenhagen, Copenhagen, Denmark

N-acyl taurine, a regulator of adipose tissue function in obesity-related metabolic disease

Anja Pammer

Medical University of Graz, Austria

Intermittent fasting and its impact on HDL function in type 2 diabetes mellitus

18:30 - 20:30 **Dinner**

09:00 - 10:45

Session 2:

Dysmetabolism and chronic inflammation

Chair: Renate Schreiber

09:00 - 09:45

Keynote lecture 1

Patrick Rensen

Leiden University Medical Center, The Netherlands

*Brown fat as target in cardiometabolic diseases:
current evidence from preclinical and clinical studies*

09:45 - 10:45

Short talks 9-12 (10 min. talk + 5 min. discussion)

Melina Amor

Medical University of Graz, Austria

*Proteomic profiling revealed networks between brown
adipose tissue and liver in a cardiometabolic mouse
model during cold exposure*

Gabriele Schoiswohl

Medical University of Graz, Austria

*Global loss of Ces2a attenuates susceptibility to
atherosclerosis in Ldlr-ko mice*

Elisabeth Ableitner

University of Graz, Austria

*Adipocyte ATGL promotes the development of athero-
sclerotic plaques*

Dragana Rajčić

Medical University of Graz, Austria

*Systemic IgA accumulation due to dysfunctional plgR
aggravates steatohepatitis*

10:45 - 11:15

Coffee break & Exhibition

11:15 - 13:00	Session 3: Regulators of the cardiovascular system homeostasis Chair: Johannes Schmid
	Short talks 13-16 (10 min. talk + 5 min. discussion)
	Susanne Sattler Medical University of Graz, Austria <i>Cardiac specific auto-antibodies in serum and tissue from coronary artery disease to ischaemic heart failure</i>
	Melissa Zenker Medical University of Vienna, Austria <i>An APRIL-targeting immunotherapy for abdominal aortic aneurysm</i>
	Alexander Peikert Medical University of Graz, Austria <i>Efficacy and safety of Dapagliflozin in patients with heart failure and previous myocardial infarction</i>
	Alexander Furlinger Medical University of Graz, Austria <i>Mechanistic insights into the cardioprotective effects of Empagliflozin in myocardial infarction: metabolomic analysis of the EMMY trial</i>
12:15 - 13:00	Keynote lecture 2
	Stephanie Dimmeler Goethe-Universität Frankfurt, Germany <i>Non-coding RNAs in the cardiovascular system</i>
13:00 - 14:00	Lunch
14:15 - 16:45	Hiking & Networking
17:00 - 19:00	Poster session
17:45 - 19:15	AAS board meeting
19:30 - 21:30	Dinner and AAS social evening

09:00 - 10:45

Session 4:
Biomarkers and networks in CVD
Chair: Christoph Säly

09:00 - 09:45

Keynote lecture 3

Wolfgang König
University of Munich, Germany
Biomarkers to define residual risk – are we there yet?

09:45 - 10:45

Short talks 17-20 (10 min. talk + 5 min. discussion)

Johannes Schmid
Medical University of Vienna, Austria
Network analysis of correlations between lifestyle factors, inflammation and cardiovascular diseases

Sophie Schmid
Medical University of Graz, Austria
Role of autophagy-related protein ATG4B in vascular biology

Olesya Harkot
Medical University of Vienna, Austria
Association of ABO blood group with long-term outcome in patients with carotid stenosis

Lucia Zisser
Medical University of Vienna, Austria
High-throughput approach to identify modulators of vasculo-inflammatory extracellular vesicle release

10:45 - 11:15

Coffee break & Exhibition

11:15 - 12:15

Session 5:

Lipolysis and lipases

Chair: Gabriele Schoiswohl

Short talks 21-24 (10 min. talk + 5 min. discussion)

Renate Schreiber

University of Graz, Austria

Nicotinic acid – revisiting an old inhibitor of cytosolic lipolysis

Anna Tilp

Medical University of Graz, Austria

Small extracellular vesicles from chylomicron-treated endothelial cells affect lipid metabolism and pro-inflammatory pathways in underlying cells

Suravi Mukherjee

Medical University of Graz, Austria

Regional differences in the small intestine proteome of control mice and of mice lacking lysosomal acid lipase

Reinhold Innerhofer

Medical University of Vienna, Austria

Austrian registry for familial hypercholesterolemia – progress report

12:15 - 13:00

Awards – sponsored by Novo Nordisk & Daiichi-Sankyo

Closing remarks

AAS General assembly (members only)



13:00

Lunch

The following posters will be shown:

- 1 Dina Alihodzic, MU Graz**
CRISPR/CAS9 genome engineering to model TET2 mutant human clonal hematopoiesis and its pro-atherogenetic potential
- 2 Richard Belciug, MU Graz**
Predicting clinical outcomes in chronic heart failure: the role of noninvasive pulse wave analysis
- 3 Katharina Brandl, MU Graz**
Beyond the arterial walls: do cardiomyocytes actively contribute to autoimmunity in heart failure?
- 4 Ida Gruber, MU Innsbruck**
Lipoprotein(a) concentrations and cardiovascular disease in chronic kidney disease patients: results from the GCKD study
- 5 Thomas Koller, MU Vienna**
Natural IgM antibodies reduce the prothrombotic potential of posttranslationally modified collagen
- 6 Andreas Leiberer, VIVIT Feldkirch**
Ceramides surpass LDL-cholesterol in predicting cardiovascular mortality in diabetic and non-diabetic patients
- 7 Eleonora Nardini, MU Vienna**
Accumulation of senescent endothelial cells exacerbates atherosclerosis and cardiovascular disease
- 8 Thomas Plattner, VIVIT Feldkirch**
Remnant cholesterol as a predictor of major cardiovascular events in cardiovascular disease patients with differing glycemic state
- 9 Clemens Röhrl, FH Wels**
Elder (Sambucus nigra), identified by high-content screening, counteracts foam cell formation without promoting hepatic lipogenesis
- 10 Laszlo Schooltink, MU Graz**
Characterization of two new lipid hydrolase candidates and the impact on lipid homeostasis
- 11 Roksana Soukhaklari, MU Graz**
Elucidation of the appropriate duration of western type diet-feeding of female Apoe^{-/-} mice for the assessment of anti-inflammatory drug effects on plaque size
- 12 Alina Stockner, MU Graz**
Targeting the white adipose tissue mitigates heart failure with preserved ejection fraction
- 13 Tamara Tomin, TU Wien**
Pyruvate kinase M2 upon oxidative injury: friend or a foe?
- 14 Anila Varghese, TU Wien**
Structural characteristics of the myocardial microcirculation in aged mice with increased cardiac IGF1 receptor signaling

AMARIN

AMGEN

The logo for Daiichi-Sankyo consists of a stylized blue circle with a yellow and green gradient on the right side.

Daiichi-Sankyo

The logo for Novartis is a stylized flame or drop shape in orange and yellow.

NOVARTIS

The logo for Novo Nordisk is a stylized blue cow with a white heart on its chest and a white ring on its head.

novo nordisk®

sanofi

The logo for Sobi is an orange circle with three white dots inside.

sobi
rare strength